Autoimmunity in 2013

Clinical Reviews in Allergy and Immunology

Volumn 47, Issue 1, 2014, Pages 100-109

  Selmi, Carlo ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Autoantibody; Rheumatoid arthritis; Systemic lupus erythematosus; Tolerance

Indexed keywords

ABATACEPT; AUTOANTIBODY; MICRORNA; MOLECULAR MARKER; MONOCLONAL ANTIBODY;

ANTIBODY BLOOD LEVEL; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; EPIGENETICS; GENOMICS; HUMAN; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PATHOGENESIS; PEER REVIEW; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TH17 CELL; TRANSLATIONAL RESEARCH; ANIMALS; AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGY; PUBLISHING; PUBMED; STATISTICS AND NUMERICAL DATA;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CLINICAL TRIALS AS TOPIC; HUMANS; PUBLISHING; PUBMED;

EID: 84906213145     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-014-8426-y     Document Type: Review

References (202)

1. Selmi C (2013) Autoimmunity in 2012. Clin Rev Allergy Immunol 45:290-301
2. Shoenfeld Y (2013) Everything is autoimmune until proven otherwise. Clin Rev Allergy Immunol 45:149-151
3. Hansel A, Gunther C, BaranWet al (2013) Human 6-sulfo LacNAc (slan) dendritic cells have molecular and functional features of an important pro-inflammatory cell type in lupus erythematosus. J Autoimmun 40:1-8
4. Chandran V (2013) The genetics of psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol 44:149-156
5. Mitra A, Fallen RS, Lima HC (2013) Cytokine-based therapy in psoriasis. Clin Rev Allergy Immunol 44:173-182
6. Raychaudhuri SP (2013) Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol 44:183-193
7. Chimenti MS, Ballanti E, Perricone C, Cipriani P, Giacomelli R, Perricone R (2013) Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways. Autoimmun Rev 12:599-606
8. Bernatsky S, Ramsey-Goldman R, Labrecque J et al (2013) Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun 42:130-135
9. Cartella S, Cavazzana I, Ceribelli A, Inverardi F, Tincani A, Franceschini F (2013) Evaluation of mortality, disease activity, treatment, clinical and immunological features of adult and late onset systemic Lupus erythematosus. Autoimmunity 46:363-368
10. Bozzolo EP, Ramirez GA, Bonavida G et al (2013) Efficacy and toxicity of treatments for nephritis in a series of consecutive lupus patients. Autoimmunity 46:537-546
11. Luijten RK, Fritsch-Stork RD, Bijlsma JW, Derksen RH (2013) The use of glucocorticoids in systemic lupus erythematosus. After 60 years still more an art than science. Autoimmun Rev 12:617-628
12. Quintero OL, Rojas-Villarraga A, Mantilla RD, Anaya JM (2013) Autoimmune diseases in the intensive care unit. An update. Autoimmun Rev 12:380-395
13. Hollan I,Meroni PL, Ahearn JM et al (2013) Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev 12:1004-1015
14. Bartoloni E, Alunno A, Bistoni O, Gerli R (2013) Cardiovascular risk in rheumatoid arthritis and systemic autoimmune rheumatic disorders: a suggested model of preventive strategy. Clin Rev Allergy Immunol 44:14-22
15. Zou YF, Xu JH, Wang F et al (2013) Association study of glucocorticoid receptor genetic polymorphisms with efficacy of glucocorticoids in systemic lupus erythematosus: a prospective cohort study. Autoimmunity 46:531-536
16. Pludowski P, Holick MF, Pilz S et al (2013) Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmun Rev 12:976-989
17. Yang CY, Leung PS, Adamopoulos IE, Gershwin ME (2013) The implication of vitamin D and autoimmunity: a comprehensive review. Clin Rev Allergy Immunol 45:217-226
18. Agmon-Levin N, Theodor E, Segal RM, Shoenfeld Y (2013) Vitamin D in systemic and organ-specific autoimmune diseases. Clin Rev Allergy Immunol 45:256-266
19. Incorvaia E, Sicouri L, Petersen-Mahrt SK, Schmitz KM (2013) Hormones and AID: balancing immunity and autoimmunity. Autoimmunity 46:128-137
20. Gonzalez J, Saha S, Peeva E (2013) Prolactin rescues and primes autoreactive B cells directly and indirectly through dendritic cells in B6.Sle3 mice. Clin Exp Immunol 172:311-320
21. Iaccarino L, Gatto M, Bettio S et al (2013) Overlap connective tissue disease syndromes. Autoimmun Rev 12:363-373
22. Tani C, D'Aniello D, Delle Sedie A et al (2013) Rhupus syndrome: assessment of its prevalence and its clinical and instrumental characteristics in a prospective cohort of 103 SLE patients. Autoimmun Rev 12:537-541
23. Gleicher N, Elkayam U (2013) Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: a review of published literature and registered clinical trials. Autoimmun Rev 12:1039-1045
24. Biazar C, Sigges J, Patsinakidis N et al (2013) Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev 12:444-454
25. Sigges J, Biazar C, Landmann A et al (2013) Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus. Autoimmun Rev 12:694-702
26. Agmon-Levin N, Selmi C (2013) The autoimmune side of heart and lung diseases. Clin Rev Allergy Immunol 44:1-5
27. Kherbeck N, Tamby MC, Bussone G et al (2013) The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension. Clin Rev Allergy Immunol 44:31-38
28. Ruiz-Irastorza G, Garmendia M, Villar I, Egurbide MV, Aguirre C (2013) Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. Autoimmun Rev 12:410-415
29. Cantarini L, Imazio M, Brizi MG et al (2013) Role of autoimmunity and autoinflammation in the pathogenesis of idiopathic recurrent pericarditis. Clin Rev Allergy Immunol 44:6-13
30. Newman K, Owlia MB, El-Hemaidi I, Akhtari M (2013) Management of immune cytopenias in patients with systemic lupus erythematosus - Old and new. Autoimmun Rev 12:784-791
31. Zheng P, Chang X, Lu Q, Liu Y (2013) Cytopenia and autoimmune diseases: a vicious cycle fueled by mTOR dysregulation in hematopoietic stem cells. J Autoimmun 41:182-187
32. Freeman ML, Burkum CE, Lanzer KG et al (2013) Gammaherpesvirus latency induces antibody-associated thrombocytopenia in mice. J Autoimmun 42:71-79
33. Samson M, Puechal X, Devilliers H et al (2013) Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. J Autoimmun 43:60-69
34. Szczeklik W, Jakiela B, Adamek D, Musial J (2013) Cutting edge issues in the Churg-Strauss syndrome. Clin Rev Allergy Immunol 44:39-50
35. Belizna C, Subra JF, Henrion D et al (2013) Prognosis of vasculitis associated myelodysplasia. Autoimmun Rev 12:943-946
36. Elhai M, Avouac J, Kahan A, Allanore Y (2013) Systemic sclerosis at the crossroad of polyautoimmunity. Autoimmun Rev 12:1052-1057
37. Colaci M, Giuggioli D, Sebastiani M et al (2013) Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature. Autoimmun Rev 12:374-379
38. Stubgen JP (2013) A literature review on optic neuritis following vaccination against virus infections. Autoimmun Rev 12:990-997
39. Zisimopoulou P, Brenner T, Trakas N, Tzartos SJ (2013) Serological diagnostics inmyasthenia gravis based on novel assays and recently identified antigens. Autoimmun Rev 12:924-930
40. Chuang WY, Strobel P, Bohlender-Willke AL et al (2013) Late-onset myasthenia gravis - CTLA4 genotype association and low-for-age thymic output of naive Tcells. J Autoimmun. doi:10.1016/j.jaut.2013.12.006
41. Jain N,Miu B, Jiang JK et al (2013) CD28 and ITK signals regulate autoreactive T cell trafficking. Nat Med 19:1632-1637
42. Meijide H, Sciascia S, Sanna G, Khamashta MA, Bertolaccini ML (2013) The clinical relevance of IgA anticardiolipin and IgA antibeta2 glycoprotein I antiphospholipid antibodies: a systematic review. Autoimmun Rev 12:421-425
43. Gualtierotti R, Biggioggero M, Meroni PL (2013) Cutting-edge issues in coronary disease and the primary antiphospholipid syndrome. Clin Rev Allergy Immunol 44:51-56
44. Zandman-Goddard G, Orbach H, Agmon-Levin N et al (2013) Hyperferritinemia is associated with serologic antiphospholipid syndrome in SLE patients. Clin Rev Allergy Immunol 44:23-30
45. Ideguchi H, Ohno S, Uehara T, Ishigatsubo Y (2013) Pregnancy outcomes in Japanese patients with SLE: retrospective review of 55 pregnancies at a university hospital. Clin Rev Allergy Immunol 44:57-64
46. Podda M, Selmi C, Lleo A, Moroni L, Invernizzi P (2013) The limitations and hidden gems of the epidemiology of primary biliary cirrhosis. J Autoimmun 46:81-87
47. Tanaka A, Takikawa H (2013) Geoepidemiology of primary sclerosing cholangitis: a critical review. J Autoimmun 46:35-40
48. Svendsen AJ, Hjelmborg JV, Kyvik KO et al (2013) The impact of genes on the occurrence of autoantibodies in rheumatoid arthritis. A study on disease discordant twin pairs. J Autoimmun 41:120-125
49. Stefan M, Zhang W, Concepcion E, Yi Z, Tomer Y (2013) DNA methylation profiles in type 1 diabetes twins point to strong epigenetic effects on etiology. J Autoimmun. doi:10.1016/j.jaut.2013.10.001
50. Sorgjerd EP, Skorpen F, Kvaloy K, Midthjell K, Grill V (2013) Prevalence of ZnT8 antibody in relation to phenotype and SLC30A8 polymorphism in adult autoimmune diabetes: results from the HUNT study, Norway. Autoimmunity 46:74-79
51. Cen H, Wang W, Leng RX et al (2013) Association of IFIH1 rs1990760 polymorphism with susceptibility to autoimmune diseases: a meta-analysis. Autoimmunity 46:455-462
52. Nezos A, Papageorgiou A, Fragoulis G, et al (2013) B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren's syndrome. J Autoimmun. doi:10.1016/j.jaut.2013.04.005
53. Sangle SR, Lutalo PM, Davies RJ, Khamashta MA, D'Cruz DP (2013) B-cell depletion therapy and pregnancy outcome in severe, refractory systemic autoimmune diseases. J Autoimmun 43:55-59
54. Kyriakidis NC, Kapsogeorgou EK, Tzioufas AG (2013) A comprehensive review of autoantibodies in primary Sjogren's syndrome: Clinical phenotypes and regulatorymechanisms. J Autoimmun. doi:10.1016/j.jaut.2013.11.001
55. Castro I, Sepulveda D, Cortes J et al (2013) Oral dryness in Sjogren's syndrome patients. Not just a question of water. Autoimmun Rev 12:567-574
56. Quartuccio L, Isola M, Baldini C, et al (2013) Biomarkers of lymphoma in Sjogren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: Results of a multicenter study. J Autoimmun. doi:10.1016/j.jaut. 2013.10.002
57. Barrera MJ, Bahamondes V, Sepulveda D et al (2013) Sjogren's syndrome and the epithelial target: a comprehensive review. J Autoimmun 42:7-18
58. Gliozzi M, Greenwell-Wild T, Jin W et al (2013) A link between interferon and augmented plasmin generation in exocrine gland damage in Sjogren's syndrome. J Autoimmun 40:122-133
59. Gatto M, Zen M, Ghirardello A et al (2013) Emerging and critical issues in the pathogenesis of lupus. Autoimmun Rev 12:523-536
60. Ben-Ami Shor D, Harel M, Eliakim R, Shoenfeld Y (2013) The hygiene theory harnessing helminths and their ova to treat autoimmunity. Clin Rev Allergy Immunol 45:211-216
61. Gianchecchi E, Delfino DV, Fierabracci A (2013) Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun Rev 12:1091-1100
62. Yang JQ, Kim PJ, Halder RC, Singh RR (2013) Intrinsic hyporesponsiveness of invariant natural killer T cells precedes the onset of lupus. Clin Exp Immunol 173:18-27
63. Simoni Y, Diana J, Ghazarian L, Beaudoin L, Lehuen A (2013) Therapeutic manipulation of natural killer (NK) T cells in autoimmunity: are we close to reality? Clin Exp Immunol 171:8-19
64. Lu MC, Lai NS, Chen HC et al (2013) Decreased microRNA(miR)-145 and increased miR-224 expression in T cells from patients with systemic lupus erythematosus involved in lupus immunopathogenesis. Clin Exp Immunol 171:91-99
65. Liu Y, Yin H, Zhao M, Lu Q (2013) TLR2 and TLR4 in Autoimmune Diseases: a Comprehensive Review. Clin Rev Allergy Immunol. doi:10.1007/s12016-013-8402-y
66. Vadasz Z, Toubi E (2013) Semaphorins: their dual role in regulating immune-mediated diseases. Clin Rev Allergy Immunol. doi:10.1007/s12016-013-8360- 4
67. Franchin G, Son M, Kim SJ, Ben-Zvi I, Zhang J, Diamond B (2013) Anti-DNA antibodies cross-react with C1q. J Autoimmun 44:34-39
68. Perricone C, Shoenfeld N, Agmon-Levin N, de Carolis C, Perricone R, Shoenfeld Y (2013) Smell and autoimmunity: a comprehensive review. Clin Rev Allergy Immunol 45:87-96
69. Sciascia S, Bertolaccini ML, Baldovino S, Roccatello D, Khamashta MA, Sanna G (2013) Central nervous system involvement in systemic lupus erythematosus: Overview on classification criteria. Autoimmun Rev 12:426-429
70. Toledano P, Sarbu N, Espinosa G, Bargallo N, Cervera R (2013) Neuropsychiatric systemic lupus erythematosus: magnetic resonance imaging findings and correlation with clinical and immunological features. Autoimmun Rev 12:1166-1170
71. Wen J, Xia Y, Stock A et al (2013) Neuropsychiatric disease inmurine lupus is dependent on the TWEAK/Fn14 pathway. J Autoimmun 43:44-54
72. Shah D, Sah S, Nath SK (2013) Interaction between glutathione and apoptosis in systemic lupus erythematosus. Autoimmun Rev 12:741-751
73. Ramirez-Ortiz ZG, Pendergraft WF 3rd, Prasad A et al (2013) The scavenger receptor SCARF1 mediates the clearance of apoptotic cells and prevents autoimmunity. Nat Immunol 14:917-926
74. Pierson W, Cauwe B, Policheni A et al (2013) Antiapoptotic Mcl-1 is critical for the survival and niche-filling capacity of Foxp3(+) regulatory T cells. Nat Immunol 14:959-965
75. Sekiya T, Kashiwagi I, Yoshida R et al (2013) Nr4a receptors are essential for thymic regulatory T cell development and immune homeostasis. Nat Immunol 14:230-237
76. Gatto M, Iaccarino L, Ghirardello A et al (2013) Serpins, immunity and autoimmunity: old molecules, new functions. Clin Rev Allergy Immunol 45:267-280
77. Mayer CT, Huntenburg J, Nandan A, Schmitt E, Czeloth N, Sparwasser T (2013) CD4 blockade directly inhibits mouse and human CD4(+) T cell functions independent of Foxp3(+) Tregs. J Autoimmun 47:73-82
78. Cui Y, Sheng Y, Zhang X (2013) Genetic susceptibility to SLE: recent progress from GWAS. J Autoimmun 41:25-33
79. Lu Q (2013) The critical importance of epigenetics in autoimmunity. J Autoimmun 41:1-5
80. Liu A, La Cava A (2013) Epigenetic dysregulation in systemic lupus erythematosus. Autoimmunity. doi:10.3109/08916934.2013.844794
81. Detanico T, St Clair JB, Aviszus K, Kirchenbaum G, Guo W, Wysocki LJ (2013) Somatic mutagenesis in autoimmunity. Autoimmunity 46:102-114
82. Schroeder K, Herrmann M, Winkler TH (2013) The role of somatic hypermutation in the generation of pathogenic antibodies in SLE. Autoimmunity 46:121-127
83. Oaks Z, Perl A (2013) Metabolic control of the epigenome in systemic Lupus erythematosus. Autoimmunity. doi:10.3109/08916934.2013.834495
84. Yang ML, Gee AJ, Gee RJ et al (2013) Lupus autoimmunity altered by cellular methylation metabolism. Autoimmunity 46:21-31
85. Wu Q, Yang Q, Sun H, Li M, Zhang Y, La Cava A (2013) Serum IFN-lambda1 is abnormally elevated in rheumatoid arthritis patients. Autoimmunity 46:40-43
86. Coit P, Jeffries M, Altorok N et al (2013) Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naive CD4+ T cells from lupus patients. J Autoimmun 43:78-84
87. Yao Y, Liu Z, Jallal B, Shen N, Ronnblom L (2013) Type I interferons in Sjogren's syndrome. Autoimmun Rev 12:558-566
88. Axtell RC, Raman C, Steinman L (2013) Type I interferons: beneficial in Th1 and detrimental in Th17 autoimmunity. Clin Rev Allergy Immunol 44:114-120
89. Zhao M, Liu Q, Liang G et al (2013) E4BP4 overexpression: a protective mechanism in CD4+ T cells from SLE patients. J Autoimmun 41:152-160
90. Zhang Y, Zhao M, Sawalha AH, Richardson B, Lu Q (2013) Impaired DNA methylation and its mechanisms in CD4(+)T cells of systemic lupus erythematosus. J Autoimmun 41:92-99
91. Fali T, Le Dantec C, Thabet Y et al (2013) DNA methylation modulates HRES1/p28 expression in B cells from patients with Lupus. Autoimmunity. doi:10.3109/08916934.2013.826207
92. Ito K, Baudino L, Kihara M et al (2013) Three Sgp loci act independently as well as synergistically to elevate the expression of specific endogenous retroviruses implicated in murine lupus. J Autoimmun 43:10-17
93. Doyle HA, Aswad DW, Mamula MJ (2013) Autoimmunity to isomerized histone H2B in systemic lupus erythematosus. Autoimmunity 46:6-13
94. Hewagama A, Gorelik G, Patel D et al (2013) Overexpression of X-linked genes in T cells from women with lupus. J Autoimmun 41:60-71
95. Koelsch KA, Webb R, Jeffries M et al (2013) Functional characterization of the MECP2/IRAK1 lupus risk haplotype in human T cells and a human MECP2 transgenic mouse. J Autoimmun 41:168-174
96. Liu Y, Wang L, Predina J et al (2013) Inhibition of p300 impairs Foxp3(+) T regulatory cell function and promotes antitumor immunity. Nat Med 19:1173-1177
97. Lodygin D, Odoardi F, Schlager C et al (2013) A combination of fluorescent NFAT and H2B sensors uncovers dynamics of T cell activation in real time during CNS autoimmunity. Nat Med 19:784-790
98. Kurko J, Besenyei T, Laki J, Glant TT, Mikecz K, Szekanecz Z (2013) Genetics of rheumatoid arthritis - a comprehensive review. Clin Rev Allergy Immunol 45:170-179
99. Trouw LA, Daha N, Kurreeman FA et al (2013) Genetic variants in the region of the C1q genes are associated with rheumatoid arthritis. Clin Exp Immunol 173:76-83
100. Yang Y, Su X, Zhang K, Zhou R (2013) The Fc receptor-like 3 gene polymorphisms and susceptibility to autoimmune diseases: an updated meta-analysis. Autoimmunity 46:547-558
101. Pratesi F, Petit Teixeira E, Sidney J et al (2013) HLA shared epitope and ACPA: just a marker or an active player? Autoimmun Rev 12:1182-1187
102. Pesce B, Soto L, Sabugo F et al (2013) Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients. Clin Exp Immunol 171:237-242
103. Goules JD, Goules AV, Tzioufas AG (2013) Fine specificity of anti-citrullinated peptide antibodies discloses a heterogeneous antibody population in rheumatoid arthritis. Clin Exp Immunol 174:10-17
104. Chighizola CB, Favalli EG, Meroni PL (2013) Novel mechanisms of action of the biologicals in rheumatic diseases. Clin Rev Allergy Immunol. doi:10.1007/s12016-013-8359-x
105. Caetano-Lopes J, Rodrigues A, Lopes A et al (2013) Rheumatoid arthritis bone fragility is associated with upregulation of IL17 and DKK1 gene expression. Clin Rev Allergy Immunol. doi:10.1007/s12016-013-8366-y
106. Gravano DM, Hoyer KK (2013) Promotion and prevention of autoimmune disease by CD8+ T cells. J Autoimmun 45:68-79
107. Carvalheiro H, da Silva JA, Souto-Carneiro MM (2013) Potential roles for CD8(+) Tcells in rheumatoid arthritis. Autoimmun Rev 12:401-409
108. Wang J, Shan Y, Jiang Z et al (2013) High frequencies of activated B cells and T follicular helper cells are correlated with disease activity in patients with new-onset rheumatoid arthritis. Clin Exp Immunol 174:212-220
109. Lee EY, Lee ZH, Song YW (2013) The interaction between CXCL10 and cytokines in chronic inflammatory arthritis. Autoimmun Rev 12:554-557
110. Savic S, Ouboussad L, Dickie LJ et al (2013) TLR dependent XBP-1 activation induces an autocrine loop in rheumatoid arthritis synoviocytes. J Autoimmun. doi:10.1016/j.jaut.2013.11.002
111. Samavedam UK, Kalies K, Scheller J et al (2013) Recombinant IL-6 treatment protects mice from organ specific autoimmune disease by IL-6 classical signalling-dependent IL-1ra induction. J Autoimmun 40:74-85
112. Liubchenko GA, Appleberry HC, Striebich CC et al (2013) Rheumatoid arthritis is associated with signaling alterations in naturally occurring autoreactive B-lymphocytes. J Autoimmun 40:111-121
113. Gonzalo-Gil E, Criado G, Santiago B, Dotor J, Pablos JL, Galindo M (2013) Transforming growth factor (TGF)-beta signalling is increased in rheumatoid synovium but TGF-beta blockade does not modify experimental arthritis. Clin Exp Immunol 174:245-255
114. Ceeraz S, Hall C, Choy EH, Spencer J, Corrigall VM (2013) Defective CD8+ CD28+ regulatory T cell suppressor function in rheumatoid arthritis is restored by tumour necrosis factor inhibitor therapy. Clin Exp Immunol 174:18-26
115. Aggarwal A, Sharma A, Bhatnagar A (2013) Bi(o)communications among peripheral blood fractions: a focus on NK and NKT cell biology in rheumatoid arthritis. Autoimmunity 46:238-250
116. Larman HB, Laserson U, Querol L et al (2013) PhIP-Seq characterization of autoantibodies from patients with multiple sclerosis, type 1 diabetes and rheumatoid arthritis. J Autoimmun 43:1-9
117. de la Rica L, Urquiza JM, Gomez-Cabrero D et al (2013) Identification of novel markers in rheumatoid arthritis through integrated analysis of DNA methylation and microRNA expression. J Autoimmun 41:6-16
118. Rinaldi M, Perricone R, Blank M, Perricone C, Shoenfeld Y (2013) Anti-Saccharomyces cerevisiae autoantibodies in autoimmune diseases: from bread baking to autoimmunity. Clin Rev Allergy Immunol 45:152-161
119. Osnes LT, Nakken B, Bodolay E, Szodoray P (2013) Assessment of intracellular cytokines and regulatory cells in patients with autoimmune diseases and primary immunodeficiencies - novel tool for diagnostics and patient follow-up. Autoimmun Rev 12:967-971
120. D'Agostino LE, Ventimiglia F, Verna JA et al (2013) Correlation between DAS-28 and neopterin as a biochemical marker of immune system activation in early rheumatoid arthritis. Autoimmunity 46:44-49
121. Atzeni F, Benucci M, Salli S, Bongiovanni S, Boccassini L, Sarzi-Puttini P (2013) Different effects of biological drugs in rheumatoid arthritis. Autoimmun Rev 12:575-579
122. Epis OM, Giacomelli L, Deidda S, Bruschi E (2013) Tight control applied to the biological therapy of rheumatoid arthritis. Autoimmun Rev 12:839-841
123. Atzeni F, Talotta R, Salaffi F et al (2013) Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev 12:703-708
124. Dimitroulas T, Nikas SN, Trontzas P, Kitas GD (2013) Biologic therapies and systemic bone loss in rheumatoid arthritis. Autoimmun Rev 12:958-966
125. Modena V, Bianchi G, Roccatello D (2013) Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target? Autoimmun Rev 12:835-838
126. Cutolo M, Nadler SG (2013) Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis. Autoimmun Rev 12:758-767
127. Atzeni F, Sarzi-Puttini P,Mutti A, Bugatti S, Cavagna L, Caporali R (2013) Long-term safety of abatacept in patients with rheumatoid arthritis. Autoimmun Rev 12:1115-1117
128. Kattah AG, Fervenza FC, Roccatello D (2013) Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases. Autoimmun Rev 12:854-859
129. Cambridge G, Perry HC, Nogueira L et al (2013) The effect of Bcell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment. J Autoimmun. doi:10.1016/j.jaut.2013.12.002
130. Shetty S, Ahmed AR (2013) Preliminary analysis of mortality associated with rituximab use in autoimmune diseases. Autoimmunity 46:487-496
131. Pineda MA, Al-Riyami L, Harnett W, Harnett M (2013) Themed Issue 2014: Lessons from helminth infections: ES-62 highlights new interventional approaches in rheumatoid arthritis. Clin Exp Immunol. doi:10.1111/cei.12252
132. Yang CL, Or TC, Ho MH, Lau AS (2013) Scientific basis of botanical medicine as alternative remedies for rheumatoid arthritis. Clin Rev Allergy Immunol 44:284-300
133. Avrameas S, Selmi C (2013) Natural autoantibodies in the physiology and pathophysiology of the immune system. J Autoimmun 41:46-49
134. Mannoor K, Xu Y, Chen C (2013) Natural autoantibodies and associated B cells in immunity and autoimmunity. Autoimmunity 46:138-147
135. Doyle HA, Yang ML, Raycroft MT, Gee RJ, Mamula MJ (2013) Autoantigens: Novel forms and presentation to the immune system. Autoimmunity. doi:10.3109/08916934.2013.850495
136. Vermeersch P, Bossuyt X (2013) Prevalence and clinical significance of rare antinuclear antibody patterns. Autoimmun Rev 12:998-1003
137. Zhu Q, Liu M, Dai L et al (2013) Using immunoproteomics to identify tumor-associated antigens (TAAs) as biomarkers in cancer immunodiagnosis. Autoimmun Rev 12:1123-1128
138. Yamada K, Ito K, Furukawa J et al (2013) Galactosylation of IgG1 modulates FcgammaRIIB-mediated inhibition of murine autoimmune hemolytic anemia. J Autoimmun 47:104-110
139. Tansley S, Gunawardena H (2013) The Evolving Spectrum of Polymyositis and Dermatomyositis-Moving Towards Clinicoserological Syndromes: A Critical Review. Clin Rev Allergy Immunol. doi:10.1007/s12016-013-8387-6
140. Hamann PD, Cooper RG, McHugh NJ, Chinoy H (2013) Statin-induced necrotizing myositis - a discrete autoimmune entity within the "statin-induced myopathy spectrum". Autoimmun Rev 12: 1177-1181
141. Muro Y, Sugiura K, Akiyama M (2013) Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients. Autoimmunity 46:279-284
142. Bazzan M, Vaccarino A, Stella S et al (2013) Thrombotic recurrences and bleeding events in APS vascular patients: a review from the literature and a comparison with the APS Piedmont Cohort. Autoimmun Rev 12:826-831
143. Radice A, Bianchi L, Sinico RA(2013) Anti-neutrophil cytoplasmic autoantibodies: methodological aspects and clinical significance in systemic vasculitis. Autoimmun Rev 12:487-495
144. Comarmond C, Cacoub P (2013) Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies. Autoimmun Rev 12:752-757
145. Avidan N, Le Panse R, Berrih-Aknin S, Miller A (2013) Genetic basis of myasthenia gravis - A comprehensive review. J Autoimmun. doi:10.1016/j.jaut. 2013.12.001
146. Zisimopoulou P, Evangelakou P, Tzartos J et al (2013) A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun. doi:10.1016/j.jaut.2013.12.004
147. Mori S, Shigemoto K (2013) Mechanisms associated with the pathogenicity of antibodies against muscle-specific kinase in myasthenia gravis. Autoimmun Rev 12:912-917
148. Evoli A, Padua L (2013) Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase. Autoimmun Rev 12:931-935
149. Dalakas MC (2013) Novel future therapeutic options in myasthenia gravis. Autoimmun Rev 12:936-941
150. Yi JS, Guidon A, Sparks S et al (2013) Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis. J Autoimmun. doi:10.1016/j.jaut.2013. 12.005
151. Verschuuren JJ, Huijbers MG, Plomp JJ et al (2013) Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev 12:918-923
152. Tuzun E, Christadoss P (2013) Complement associated pathogenic mechanisms in myasthenia gravis. Autoimmun Rev 12:904-911
153. Gertel-Lapter S, Mizrachi K, Berrih-Aknin S, Fuchs S, Souroujon MC (2013) Impairment of regulatory T cells in myasthenia gravis: studies in an experimental model. Autoimmun Rev 12:894-903
154. Marx A, Pfister F, Schalke B, Saruhan-Direskeneli G, Melms A, Strobel P (2013) The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 12:875-884
155. Noel N, Andre C, Bengoufa D et al (2013) Performance evaluation of three assays for the detection of PR3-ANCA in granulomatosis with polyangiitis in daily practice. Autoimmun Rev 12:1118-1122
156. Dammacco F, Battaglia S, Gesualdo L, Racanelli V (2013) Goodpasture's disease: a report of ten cases and a review of the literature. Autoimmun Rev 12:1101-1108
157. Sinico RA, Di Toma L, Radice A (2013) Renal involvement in antineutrophil cytoplasmic autoantibody associated vasculitis. Autoimmun Rev 12:477-482
158. Arias-Loste MT, Bonilla G, Moraleja I et al (2013) Presence of anti-proteinase 3 antineutrophil cytoplasmic antibodies (anti-PR3 ANCA) as serologic markers in inflammatory bowel disease. Clin Rev Allergy Immunol 45:109-116
159. Pengo V, Banzato A, Denas G et al (2013) Correct laboratory approach to APS diagnosis and monitoring. Autoimmun Rev 12:832-834
160. Viall CA, Chen Q, Liu B et al (2013) Antiphospholipid antibodies internalised by human syncytiotrophoblast cause aberrant cell death and the release of necrotic trophoblast debris. J Autoimmun 47:45-57
161. Andreoli L, Fredi M, Nalli C, Franceschini F, Meroni PL, Tincani A (2013) Antiphospholipid antibodies mediate autoimmunity against dying cells. Autoimmunity 46:302-306
162. Floreani A, Liberal R, Vergani D, Mieli-Vergani G (2013) Autoimmune hepatitis: contrasts and comparisons in children and adults - a comprehensive review. J Autoimmun 46:7-16
163. Imam MH, Talwalkar JA, Lindor KD (2013) Clinical management of autoimmune biliary diseases. J Autoimmun 46:88-96
164. Liberal R, Grant CR, Mieli-Vergani G, Vergani D (2013) Autoimmune hepatitis: a comprehensive review. J Autoimmun 41:126-139
165. Gatselis NK, Zachou K, Norman GL et al (2013) Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. Autoimmunity 46:471-479
166. Wang Q, Selmi C, Zhou X et al (2013) Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis. J Autoimmun 41:140-145
167. Tsuneyama K, Baba H, Kikuchi K et al (2013) Autoimmune features in metabolic liver disease: a single-center experience and review of the literature. Clin Rev Allergy Immunol 45:143-148
168. Trivedi PJ, Adams DH (2013) Mucosal immunity in liver autoimmunity: a comprehensive review. J Autoimmun 46:97-111
169. Leung PS, Wang J, Naiyanetr P et al (2013) Environment and primary biliary cirrhosis: electrophilic drugs and the induction of AMA. J Autoimmun 41:79-86
170. Lleo A, Oertelt-Prigione S, Bianchi I et al (2013) Y chromosome loss in male patients with primary biliary cirrhosis. J Autoimmun 41:87-91
171. Efe C (2013) Drug induced autoimmune hepatitis and TNF-alpha blocking agents: is there a real relationship? Autoimmun Rev 12:337-339
172. Longhi MS, Ma Y, Grant CR et al (2013) T-regs in autoimmune hepatitis-systemic lupus erythematosus/mixed connective tissue disease overlap syndrome are functionally defective and display a Th1 cytokine profile. J Autoimmun 41:146-151
173. Muratori L, Longhi MS (2013) The interplay between regulatory and effector T cells in autoimmune hepatitis: Implications for innovative treatment strategies. J Autoimmun 46:74-80
174. Ehser J, Holdener M, Christen S et al (2013) Molecular mimicry rather than identity breaks T-cell tolerance in the CYP2D6 mouse model for human autoimmune hepatitis. J Autoimmun 42:39-49
175. Dias PM, Banerjee G (2013) The role of Th17/IL-17 on eosinophilic inflammation. J Autoimmun 40:9-20
176. Rangachari M, Kuchroo VK (2013) Using EAE to better understand principles of immune function and autoimmune pathology. J Autoimmun 45:31-39
177. Kim JS, Sklarz T, Banks LB et al (2013) Natural and inducible TH17 cells are regulated differently by Akt and mTOR pathways. Nat Immunol 14:611-618
178. Milpied PJ, McHeyzer-Williams MG (2013) High-affinity IgA needs TH17 cell functional plasticity. Nat Immunol 14:313-315
179. Ji Q, Castelli L, Goverman JM (2013) MHC class I-restricted myelin epitopes are cross-presented by Tip-DCs that promote determinant spreading to CD8(+) T cells. Nat Immunol 14:254-261
180. Mascanfroni ID, Yeste A, Vieira SMet al (2013) IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat Immunol 14:1054-1063
181. Xiao J, Liu C, Li G et al (2013) PDCD5 negatively regulates autoimmunity by upregulating FOXP3(+) regulatory T cells and suppressing Th17 and Th1 responses. J Autoimmun 47:34-44
182. Chong WP, Horai R, Mattapallil MJ et al (2013) IL-27p28 inhibits central nervous system autoimmunity by concurrently antagonizing Th1 and Th17 responses. J Autoimmun. doi:10.1016/j.jaut.2013.08.003
183. Jin JO, Han X, Yu Q (2013) Interleukin-6 induces the generation of IL-10-producing Tr1 cells and suppresses autoimmune tissue inflammation. J Autoimmun 40:28-44
184. Romo-Tena J, Gomez-Martin D, Alcocer-Varela J (2013) CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance. Autoimmun Rev 12:1171-1176
185. Singh RP, Massachi I, Manickavel S et al (2013) The role ofmiRNA in inflammation and autoimmunity. Autoimmun Rev 12:1160-1165
186. Jimenez SA, Piera-Velazquez S (2013) Potential role of human-specific genes, human-specific microRNAs and human-specific non-coding regulatory RNAs in the pathogenesis of systemic sclerosis and Sjogren's syndrome. Autoimmun Rev 12:1046-1051
187. Cohen C, Mekinian A, Uzunhan Y et al (2013) 18F-fluorodeoxyglucose positron emission tomography/computer tomography as an objective tool for assessing disease activity in Sjogren's syndrome. Autoimmun Rev 12:1109-1114
188. Guellec D, Cornec D, Jousse-Joulin S et al (2013) Diagnostic value of labial minor salivary gland biopsy for Sjogren's syndrome: a systematic review. Autoimmun Rev 12:416-420
189. Priori R, Scrivo R, Brandt J et al (2013)Metabolomics in rheumatic diseases: the potential of an emerging methodology for improved patient diagnosis, prognosis, and treatment efficacy. Autoimmun Rev 12:1022-1030
190. Bogdanos DP, Smyk DS, Invernizzi P et al (2013) Infectome: a platform to trace infectious triggers of autoimmunity. Autoimmun Rev 12:726-740
191. Wichner K, Fischer A, Winter S et al (2013) Transition from an autoimmune-prone state to fatal autoimmune disease in CCR7 and RORgammat double-deficient mice is dependent on gut microbiota. J Autoimmun 47:58-72
192. Cuadrado MJ, Sciascia S, Bosch X, Khamashta MA, Ramos-Casals M (2013) Is it time for biosimilars in autoimmune diseases? Autoimmun Rev 12:954-957
193. Cipriani P, Carubbi F, Liakouli Vet al (2013) Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy. Autoimmun Rev 12:709-716
194. Perricone C, Colafrancesco S, Mazor RD, Soriano A, Agmon-Levin N, Shoenfeld Y (2013) Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects. J Autoimmun 47:1-16
195. Frisenda S, Perricone C, Valesini G (2013) Cartilage as a target of autoimmunity: a thin layer. Autoimmun Rev 12:591-598
196. Goebel A, Blaes F (2013) Complex regional pain syndrome, prototype of a novel kind of autoimmune disease. Autoimmun Rev 12:682-686
197. Gesundheit B, Rosenzweig JP, Naor D et al (2013) Immunological and autoimmune considerations of Autism Spectrum Disorders. J Autoimmun 44:1-7
198. Katzav A, Arango MT, Kivity S et al (2013) Passive transfer of narcolepsy: anti-TRIB2 autoantibody positive patient IgG causes hypothalamic orexin neuron loss and sleep attacks in mice. J Autoimmun 45:24-30
199. Singh AK, Mahlios J, Mignot E (2013) Genetic association, seasonal infections and autoimmune basis of narcolepsy. JAutoimmun 43:26-31
200. Nussinovitch U, Shoenfeld Y (2013) The clinical and diagnostic significance of anti-myosin autoantibodies in cardiac disease. Clin Rev Allergy Immunol 44:98-108
201. Nussinovitch U, Shoenfeld Y (2013) The clinical significance of anti-beta-1 adrenergic receptor autoantibodies in cardiac disease. Clin Rev Allergy Immunol 44:75-83
202. Roux-Lombard P, Pagano S, Montecucco F, Satta N, Vuilleumier N (2013) Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases. Clin Rev Allergy Immunol 44:84-97